Total raised
$18.5M
Last: Series C 2022-07
Stage
Series C
Founded
2012
Headcount
9
HQ
Kiryat Ono
Sector
Health Tech & Life Sciences
About
Sanoculis offers a new alternative surgical procedure for treating glaucoma. Its Minimally Invasive Micro Sclerostomy (MIMS) solution consists of a single-patient-use sterile tool and a multi-use external machine. In the course of the surgery, a sclero-corneal drainage channel is created to reduce intraocular pressure. MIMS is a microfluidic full-thickness procedure developed as an advanced laser sclerostomy. The technique uses a cutting and drilling device to reduce trauma to the surrounding tissue, minimizing scar tissue formation and allowing for a long-lasting filtering bleb. The MIMS channel ensures a controlled fluid flow with minor complications. In March 2017, Sanoculis was granted CE marking for its MIMS device and procedure.
Funding history · 3 rounds · $18.5M total
2022-07
Series C
$14.0M
2019-09
Series B
Undisclosed
2016-08
Series A
$1.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
SensingLaser
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
1 PatentsVerified
Tags
minimally-invasivesurgeryglaucomahospitalssurgeonsophthalmologymedical-deviceshealthcare-providerseye-diseasesclinicstreatments